Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adynxx, Inc.ADYX · Entity 155807 | Director | July 22, 2019 | July 29, 2019 |
| Eledon Pharmaceuticals, Inc.NVUS · Entity 6160 | Director · Chief Executive Officer | March 19, 2020 | March 20, 2020 |
| OnKure Therapeutics, Inc.RPHM · Entity 6550 | Director · President and CEO | December 09, 2022 | December 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adynxx, Inc.
Report date July 22, 2019 · Filed July 29, 2019
This filing explicitly reported no securities owned.
Eledon Pharmaceuticals, Inc.
Report date March 19, 2020 · Filed March 20, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.26 · Expires 2030-03-19 | Direct | 200,000 |
Reported balance
After 2020-03-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-19 · Grant · Acquired 200,000 · Balance 200,000 F1: This option represents a right to purchase a total of 200,000 shares of the Issuer's Common Stock, one quarter of which will become fully vested and exercisable on March 19, 2021, with the remaining 150,000 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 200,000 shares of the Issuer's Common Stock, one quarter of which will become fully vested and exercisable on March 19, 2021, with the remaining 150,000 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.
OnKure Therapeutics, Inc.
Report date December 09, 2022 · Filed December 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2032-12-08 | Direct | 300,000 |
Reported balance
After 2022-12-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-12-09 · Grant · Acquired 300,000 · Balance 300,000 F2: The shares vest in a series of 16 equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date. |
| Common StockSEC Table I · non-derivative | Direct | 115,200 |
Reported balance
Holding disclosure · report date 2022-12-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 115,200 F1: Includes 1,600 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on June 8, 2022 and 4,000 shares acquired under the Plan on December 8, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 1,600 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on June 8, 2022 and 4,000 shares acquired under the Plan on December 8, 2022.
F2: The shares vest in a series of 16 equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2022 Filed Dec 13, 2022 23:09 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock option (right to buy) · Derivative | 300,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001209191-22-061034 · doc4.xml · derivative · entry 2 FLESHER GREGORY J. · CIK 0001705287 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-12-08 F2 · derivative.exercise_date: The shares vest in a series of 16 equal quarterly installments measured from December 9, 2022 subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 21:31 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $6.69 | $0.00 |
DisclosureSEC source: 0001209191-21-069443 · doc4.xml · derivative · entry 2 FLESHER GREGORY J. · CIK 0001705287 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-12-09 F3 · derivative.exercise_date: The shares vest in a series of 48 successive equal monthly installments measured from December 10, 2021, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 21:31 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069443 · doc4.xml · nonDerivative · entry 1 FLESHER GREGORY J. · CIK 0001705287 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,600 F1 · shares: Represents a restricted stock unit award. F2 · balance_after: Includes 1,600 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on December 8, 2021. Read SEC document |
| August 25, 2021 Filed Aug 26, 2021 21:52 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | PurchaseCommon Stock | 8,000 | $8.00 | $64,000.00 |
DisclosureSEC source: 0001209191-21-053522 · doc4.xml · nonDerivative · entry 1 FLESHER GREGORY J. · CIK 0001705287 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Read SEC document |
| March 19, 2020 Filed Mar 20, 2020 20:31 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0000899243-20-009126 · doc4.xml · derivative · entry 1 FLESHER GREGORY J. · CIK 0001705287 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-03-19 F1 · derivative.exercise_date: This option represents a right to purchase a total of 200,000 shares of the Issuer's Common Stock, one quarter of which will become fully vested and exercisable on March 19, 2021, with the remaining 150,000 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| September 26, 2019 Filed Oct 1, 2019 01:30 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0000899243-19-024431 · doc4.xml · derivative · entry 1 FLESHER GREGORY J. · CIK 0001705287 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-09-26 F1 · derivative.exercise_date: This option represents a right to purchase a total of 100,000 shares of the Issuer's Common Stock, which will vest in equal installments on the first and second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| May 21, 2019 Filed May 22, 2019 20:01 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | SaleCommon Stock | 2,937 | $1.91 | $5,613.78 |
DisclosureSEC source: 0001562180-19-003051 · primarydocument.xml · nonDerivative · entry 2 FLESHER GREGORY J. · CIK 0001705287 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,918 F1 · kind: Shares were sold to cover the reporting person's taxes due on the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $1.90 to $1.945. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 20, 2019 Filed May 22, 2019 20:01 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | SaleCommon Stock | 11,701 | $1.96 | $22,952.68 |
DisclosureSEC source: 0001562180-19-003051 · primarydocument.xml · nonDerivative · entry 1 FLESHER GREGORY J. · CIK 0001705287 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,855 F1 · kind: Shares were sold to cover the reporting person's taxes due on the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.90 to $2.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 20:23 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0000899243-19-008140 · doc4.xml · derivative · entry 2 FLESHER GREGORY J. · CIK 0001705287 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-03-14 F2 · derivative.exercise_date: This option represents a right to purchase a total of 90,000 shares of the Issuer's Common Stock, which will vest in equal quarterly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 20:23 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-008140 · doc4.xml · nonDerivative · entry 1 FLESHER GREGORY J. · CIK 0001705287 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,556 F1 · price: This represents restricted stock units representing the right to receive shares of the Issuer's Common Stock, which will vest in full on the later of achievement of a performance-related goal or the first anniversary of the grant date. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 22:51 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 56,500 | $0.00 Strike: $4.83 | $0.00 |
DisclosureSEC source: 0000899243-18-007647 · doc4.xml · derivative · entry 2 FLESHER GREGORY J. · CIK 0001705287 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,500 Underlying: Common Stock · 56,500 shares Expires 2028-03-13 F2 · derivative.exercise_date: This option represents a right to purchase a total of 56,500 shares of the Issuer's Common Stock, one quarter of which will become fully vested and exercisable on March 13, 2019, with the remaining 42,375 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 22:51 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantCommon Stock | 30,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-007647 · doc4.xml · nonDerivative · entry 1 FLESHER GREGORY J. · CIK 0001705287 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,556 F1 · price: This represents restricted stock units representing the right to receive shares of the Issuer's Common Stock, which will vest in full on the later of achievement of a performance-related goal or the first anniversary of the grant date. Read SEC document |
| May 24, 2017 Filed May 26, 2017 20:06 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0000899243-17-014542 · doc4.xml · derivative · entry 1 FLESHER GREGORY J. · CIK 0001705287 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-05-23 F1 · derivative.exercise_date: This option represents a right to purchase a total of 250,000 shares of the Issuer's Common Stock. 150,000 shares will vest ratably each month over three years beginning on May 24, 2017 (the "grant date"). 100,000 shares will vest on the later of achievement of a performance-related goal or the first anniversary of the grant date. Read SEC document |
| May 10, 2017 Filed May 12, 2017 00:36 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | PurchaseCommon Stock | 58,959 | $9.99 | $589,000.41 |
DisclosureSEC source: 0000899243-17-012936 · doc4.xml · nonDerivative · entry 1 FLESHER GREGORY J. · CIK 0001705287 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,856 F1 · shares: All numbers give effect to the 1:9 reverse stock split effected by the Issuer on May 11, 2017. F1 · balance_after: All numbers give effect to the 1:9 reverse stock split effected by the Issuer on May 11, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.